• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.卵巢癌中多种生物标志物的检测与分析:在诊断、治疗及预后评估中的临床意义
Gland Surg. 2020 Dec;9(6):2175-2186. doi: 10.21037/gs-20-811.
2
Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry.中国人的腹膜假黏液瘤的组织学起源:临床病理和免疫组织化学。
World J Gastroenterol. 2011 Aug 14;17(30):3531-7. doi: 10.3748/wjg.v17.i30.3531.
3
Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer.鉴定肺癌中细胞角蛋白 20 和细胞角蛋白 7 表达的相关预后价值。
Biosci Rep. 2017 Nov 6;37(6). doi: 10.1042/BSR20171086. Print 2017 Dec 22.
4
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.FIGO 分期 IV 期上皮性卵巢癌患者中预处理血小板计数和 CA125 水平(PLT-CA125)联合评分的预后分层。
J Ovarian Res. 2019 Jul 31;12(1):72. doi: 10.1186/s13048-019-0544-y.
5
Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer.标题:ZEB2 和 TGF-β1 及其他临床特征在卵巢上皮性癌中的预后意义。
Int J Gynecol Cancer. 2017 Sep;27(7):1343-1349. doi: 10.1097/IGC.0000000000001037.
6
Correlation analysis of Ki67 and CK7 expression with clinical characteristics and prognosis of postoperative cervical adenocarcinoma patients.Ki67 和 CK7 表达与术后宫颈腺癌患者临床特征及预后的相关性分析。
Ann Palliat Med. 2021 Sep;10(9):9544-9552. doi: 10.21037/apm-21-1974.
7
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.雌激素受体和孕激素受体肿瘤表达在丹麦卵巢癌患者中的预后价值:来自“MALOVA”卵巢癌研究
Oncol Rep. 2007 Nov;18(5):1051-9.
8
Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis.与无合并子宫内膜异位症的卵巢癌相比,子宫内膜异位症相邻的卵巢癌组织中环氧合酶-2的表达更高。
Eur J Obstet Gynecol Reprod Biol. 2006 Jan 1;124(1):101-5. doi: 10.1016/j.ejogrb.2005.06.019.
9
Primary peritoneal serous papillary carcinoma: a clinical and pathological study.原发性腹膜浆液性乳头状癌:临床与病理研究。
Pathol Oncol Res. 2011 Sep;17(3):713-9. doi: 10.1007/s12253-011-9375-x. Epub 2011 Jun 7.
10
Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.与成熟囊性畸胎瘤相关的卵巢黏液性肿瘤:形态学和免疫组化分析确定了一个潜在畸胎瘤起源的亚组,该亚组具有在卵巢中更常见的作为继发性肿瘤的下消化道黏液性肿瘤的特征。
Am J Surg Pathol. 2007 Jun;31(6):854-69. doi: 10.1097/PAS.0b013e31802efb45.

引用本文的文献

1
Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches.长链非编码RNA、微小RNA和环状RNA在卵巢癌转移中的作用:途径与治疗方法
Reprod Sci. 2025 Aug 15. doi: 10.1007/s43032-025-01948-x.
2
Revisiting the use of CK7 and CK20 immunohistochemical stains in pathological diagnoses.重新审视细胞角蛋白7和细胞角蛋白20免疫组化染色在病理诊断中的应用。
Diagn Pathol. 2025 Apr 11;20(1):40. doi: 10.1186/s13000-025-01638-x.
3
An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.卵巢癌实验模型:卵巢癌起始细胞的增殖和卵巢癌类器官的生成。
BMC Cancer. 2022 Sep 10;22(1):967. doi: 10.1186/s12885-022-10042-3.
4
Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.系统分析卵巢癌预后与可变剪接的关系。
J Ovarian Res. 2021 Sep 15;14(1):120. doi: 10.1186/s13048-021-00866-1.

本文引用的文献

1
Clinicopathologic factors associated with short-term survival in advanced epithelial ovarian cancer.与晚期上皮性卵巢癌短期生存相关的临床病理因素
Transl Cancer Res. 2019 Oct;8(6):2396-2404. doi: 10.21037/tcr.2019.09.53.
2
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
3
Principles of clinical management of ovarian cancer.卵巢癌临床管理原则
Chin Clin Oncol. 2018 Dec;7(6):56. doi: 10.21037/cco.2018.10.06.
4
High LIN28A and PLK4 co‑expression is associated with poor prognosis in epithelial ovarian cancer.高 LIN28A 和 PLK4 的共表达与上皮性卵巢癌的不良预后相关。
Mol Med Rep. 2018 Dec;18(6):5327-5336. doi: 10.3892/mmr.2018.9562. Epub 2018 Oct 16.
5
Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.核 β-连环蛋白和 CDX2 在卵巢子宫内膜样癌中的表达可识别预后良好的患者。
Histopathology. 2019 Feb;74(3):452-462. doi: 10.1111/his.13772.
6
Cancer Statistics for Hispanics/Latinos, 2018.2018 年西班牙裔/拉丁裔癌症统计数据。
CA Cancer J Clin. 2018 Nov;68(6):425-445. doi: 10.3322/caac.21494. Epub 2018 Oct 4.
7
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
8
Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.卵巢癌和交界性肿瘤妇女的生存不受雌激素和孕激素受体状态的影响。
J Gynecol Oncol. 2013 Apr;24(2):167-76. doi: 10.3802/jgo.2013.24.2.167. Epub 2013 Apr 5.
9
Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.盆腔肿块的鉴别诊断:改良算法和新型生物标志物。
Int J Gynecol Cancer. 2012 May;22 Suppl 1(Suppl 1):S5-8. doi: 10.1097/IGC.0b013e318251c97d.
10
PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.PDX-1、CDX-2、TTF-1 和 CK7:用于胰腺神经内分泌肿瘤的可靠免疫组化标志物。
Am J Surg Pathol. 2012 May;36(5):737-43. doi: 10.1097/PAS.0b013e31824aba59.

卵巢癌中多种生物标志物的检测与分析:在诊断、治疗及预后评估中的临床意义

Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.

作者信息

Ji Rui, Li Yong, He Chenyun, Zhu Xinghua, He Aiqin, Lu Yunyan

机构信息

Department of Gynecology, Affiliated Cancer Hospital of Nantong University, Nantong, China.

Department of Pathology, Affiliated Cancer Hospital of Nantong University, Nantong, China.

出版信息

Gland Surg. 2020 Dec;9(6):2175-2186. doi: 10.21037/gs-20-811.

DOI:10.21037/gs-20-811
PMID:33447568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7804549/
Abstract

BACKGROUND

The purpose of this study was to explore the clinical significance of CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp in ovarian cancer.

METHODS

Ovarian cancer patients were recruited from Nantong Cancer Hospital between March 2006 and July 2011. The expressions of CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp were determined by immunohistochemistry (IHC).The chi-square test (χ) was used to analyze the correlation between each index and the clinical characteristics of the patients. The patients were followed up to record the cancer recurrence time. The Kaplan-Meier method was used to map the cumulative recurrence-free survival (RFS) rate, and COX regression analysis was established for multivariate analysis.

RESULTS

The results of IHC showed that the positive expression rates of CA125, CK7, ER, C-erbb2, and P-gp in malignant ovarian cancer tissues were significantly higher than those in benign ovarian cancer tissues. CA125 expression in malignant ovarian cancer was significantly correlated with the age of patients and the Federation of International Gynecology and Obstetrics (FIGO) stage. CK7 expression in malignant ovarian cancer was significantly correlated with the age, tissue differentiation, and number of residual lesions. CK20 expression in malignant ovarian cancer was significantly correlated with the age and tissue differentiation of the patients. ER expression in malignant ovarian cancer was significantly correlated with the age of patients and FIGO stage. PR expression in malignant ovarian cancer was significantly correlated with the age of the patients. C-erbb2 expression in malignant ovarian cancer was significantly correlated with the age of the patients. P-gp expression in malignant ovarian cancer was significantly correlated with the patient age, pathological type, and tissue differentiation. The expression of CA125, CK7, CK20, C-erbb2, and P-gp had significant effects on the prognosis of patients with ovarian cancer. The COX regression analysis showed that was an independent risk factor for ovarian cancer.

CONCLUSIONS

In malignant ovarian cancer tissues, CA125, CK7, CK20, ER, PR, C-erbb2, and P-gp are over-expressed. The expression of P-gp is an independent risk factor for ovarian cancer, and it can be an important target for the treatment of malignant ovarian cancer.

摘要

背景

本研究旨在探讨CA125、细胞角蛋白7(CK7)、细胞角蛋白20(CK20)、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(C-erbb2)和P-糖蛋白(P-gp)在卵巢癌中的临床意义。

方法

选取2006年3月至2011年7月在南通肿瘤医院就诊的卵巢癌患者。采用免疫组织化学法检测CA125、CK7、CK20、ER、PR、C-erbb2和P-gp的表达。采用卡方检验分析各指标与患者临床特征的相关性。对患者进行随访,记录癌症复发时间。采用Kaplan-Meier法绘制累积无复发生存率(RFS)曲线,并进行COX回归分析以进行多因素分析。

结果

免疫组织化学结果显示,恶性卵巢癌组织中CA125、CK7、ER、C-erbb2和P-gp的阳性表达率显著高于良性卵巢癌组织。恶性卵巢癌中CA125的表达与患者年龄及国际妇产科联盟(FIGO)分期显著相关。恶性卵巢癌中CK7的表达与年龄、组织分化程度及残留病灶数量显著相关。恶性卵巢癌中CK20的表达与患者年龄及组织分化程度显著相关。恶性卵巢癌中ER的表达与患者年龄及FIGO分期显著相关。恶性卵巢癌中PR的表达与患者年龄显著相关。恶性卵巢癌中C-erbb2的表达与患者年龄显著相关。恶性卵巢癌中P-gp的表达与患者年龄、病理类型及组织分化程度显著相关。CA125、CK7、CK20、C-erbb2和P-gp的表达对卵巢癌患者的预后有显著影响。COX回归分析显示,[此处原文缺失具体内容]是卵巢癌的独立危险因素。

结论

在恶性卵巢癌组织中,CA125、CK7、CK20、ER、PR、C-erbb2和P-gp呈过度表达。P-gp的表达是卵巢癌的独立危险因素,可成为恶性卵巢癌治疗的重要靶点。